{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"14.0","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression as assessed by the study IRC or death from any cause. PFS was analyzed using KM estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Start of Treatment to End of Treatment (up to 81 months)","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}